Source: Yahoo Finance
Late-stage biotech Novavax ( NVAX) has announced the beginning of a Phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate.
NVX‑CoV2373 is a stable, prefusion protein made using the company’s nanoparticle technology and Matrix‑M adjuvant, which is designed to enhance the immune response and stimulate high levels of neutralizing antibodies.
Dr. Shabir Madhi, Professor of Vaccinology at Wits University, will lead the clinical trial, which is supported in part by a $15 million grant from the Bill & Melinda Gates Foundation.
“Because South Africa is experiencing a winter surge of COVID-19 disease, this important Phase 2b clinical trial has the potential to provide an early indication of efficacy, along with additional safety and immunogenicity data for NVX-CoV2373,” said Gregory…
View original post 522 more words